CoChat

Topiramate reduces nocturnal eating in sleep-related eating disorder

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Study Objectives: Sleep-related eating disorder (SRED) is a parasomnia characterized by partial arousals from sleep with compulsive consumption of food with impaired level of awareness and memory for the event. Small case series’ have demonstrated efficacy of topiramate in SRED. We conducted a placebo-controlled randomized clinical trial of topiramate to assess efficacy in SRED. Methods: Thirty-four participants with an ICSD-2/ICSD-3 diagnosis of SRED with >6 months of symptoms and ≥3 sleep-related eating episodes per week were randomized to placebo or topiramate with flexible dosing to a maximum dosage of 300 mg for 13 weeks. Primary outcomes were percentage of nights with eating and Clinician Global Impression-Improvement (CGI-I). Intention-to-treat last observation carried forward (ITT LOCF) analysis was conducted. Results: Mean age was 39.5 years, 74% were female, with mean duration of sleep-related eating of 13.7 years. SRED symptoms were significantly reduced with topiramate (74.7% to 33.2% nights/week; n = 15) compared to placebo (77.0% to 57.4%; n = 17) (p = 0.035). There were significantly more CGI-I responders on topiramate (71%) than placebo (27%) (p = 0.016). Level of wakefulness (r = −0.49) and memory for nighttime eating (r = −0.58) at baseline predicted topiramate response. The topiramate group lost significantly more weight than the placebo group (−8.5 lbs vs. +1.0 lbs, p = 0.001). The most common side effects were paresthesias and cognitive dysfunction. Conclusions: This first randomized controlled trial demonstrating efficacy for treatment of SRED supports preliminary data on the use of topiramate for SRED. Side effects were prominent for topiramate. Limitations include a small sample size and a high drop-out rate in both study groups. Clinical Trial Information: NCT00606411

Overview

Integrity signals

Registry

Crossref · 10.1093/sleep/zsaa060

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Research works printed but not linked: 2

  1. Schenck, 2006, Topiramate therapy of sleep-related eating disorder (SRED), Sleep, 29, A268
  2. American Academy of Sleep Medicine., 2005, International Classification of Sleep Disorders

Cited by

See all 34

Metadata

Authors
Winkelman, J. W., Wipper, B., Purks, J., Mei, L., & Schoerning, L.
Affiliations
  • Harvard University (US)
  • Massachusetts General Hospital (US)
  • University of Vermont (US)
  • University of Wisconsin–Madison (US)
  • University of Massachusetts Chan Medical School (US)
Corresponding author
Winkelman, John W
Venue
Sleep
Published
2020-03-30
Volume
43
Issue
9
ISSN
  • 0161-8105 (ISSN-L)
  • 1550-9109
OpenAlex
W3013599866
Cited by
32
References
35
Citations by year
2026: 2 · 2025: 5 · 2024: 2 · 2023: 9 · 2022: 6 · 2021: 5 · 2020: 3
FWCI
5.56
Type
journal article
Language
en
Open access
closed
Locations
  • SLEEP (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
  • Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
Keywords
sleep-related eating disorder, topiramate, night eating, parasomnias, anticonvulsant therapy, weight loss, wakefulness, predictors of treatment response, cognitive impairment, paresthesia
MeSH terms
Topiramate, Adult, Feeding and Eating Disorders, Double-Blind Method, Female, Fructose, Humans, Male, Sleep, Sleep Wake Disorders, Treatment Outcome, Parasomnias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Topiramate reduces nocturnal eating in sleep-related eating disorder. https://app.cochat.ai/papers/10.1093/sleep/zsaa060
The paper
Winkelman, J. W., Wipper, B., Purks, J., Mei, L., & Schoerning, L. (2020). Topiramate reduces nocturnal eating in sleep-related eating disorder. Sleep. https://doi.org/10.1093/sleep/zsaa060

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.